Biomarker-guided preemption of steroid-refractory graft-versus-host disease with α-1-antitrypsin
| Autor: | Ryotaro Nakamura, Wolf Rösler, Isha Gandhi, Stelios Kasikis, Janna Baez, John E. Levine, Francis Ayuk, Kaitlyn Ben-David, Hannah K. Choe, Hrishikesh K. Srinagesh, Udomsak Bunworasate, Pietro Merli, Mina Aziz, Steven Kowalyk, George Morales, Jung-Yi Lin, Umut Ozbek, Elizabeth O. Hexner, Zachariah DeFilipp, James L.M. Ferrara, Yi-Bin Chen, Aaron Etra, Stephanie Gergoudis, Carrie L. Kitko, Karamjeet S. Sandhu, William J. Hogan, Rachel Young, Ernst Holler, Ran Reshef |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
business.industry Clinical Trials and Observations Incidence (epidemiology) Hematopoietic Stem Cell Transplantation Graft vs Host Disease α 1 antitrypsin Hematology Disease medicine.disease_cause medicine.disease Gastroenterology Transplantation Graft-versus-host disease surgical procedures operative immune system diseases Internal medicine medicine Biomarker (medicine) Humans Steroids Steroid refractory Carcinogenesis business Biomarkers |
| Zdroj: | Blood Adv |
| Popis: | Steroid-refractory (SR) acute graft-versus-host disease (GVHD) remains a major cause of nonrelapse mortality (NRM) after allogeneic hematopoietic cell transplantation (HCT), but its occurrence is not accurately predicted by pre-HCT clinical risk factors. The Mount Sinai Acute GVHD International Consortium (MAGIC) algorithm probability (MAP) identifies patients who are at high risk for developing SR GVHD as early as 7 days after HCT based on the extent of intestinal crypt damage as measured by the concentrations of 2 serum biomarkers, suppressor of tumorigenesis 2 and regenerating islet-derived 3α. We conducted a multicenter proof-of-concept “preemptive” treatment trial of α-1-antitrypsin (AAT), a serine protease inhibitor with demonstrated activity against GVHD, in patients at high risk for developing SR GVHD. Patients were eligible if they possessed a high-risk MAP on day 7 after HCT or, if initially low risk, became high risk on repeat testing at day 14. Thirty high-risk patients were treated with twice-weekly infusions of AAT for a total of 16 doses, and their outcomes were compared with 90 high-risk near-contemporaneous MAGIC control patients. AAT treatment was well tolerated with few toxicities, but it did not lower the incidence of SR GVHD compared with controls (20% vs 14%, P = .56). We conclude that real-time biomarker-based risk assignment is feasible early after allogeneic HCT but that this dose and schedule of AAT did not change the incidence of SR acute GVHD. This trial was registered at www.clinicaltrials.gov as #NCT03459040. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|